5-(Chloromethyl)Thiazole Hcl

The compound is supplied as a white to off-white crystalline powder with a typical purity of ≥98.0% by HPLC, often on a solvent-free basis. Water content, determined by Karl Fischer titration, is routinely controlled below 0.5% because the free base form—liberated upon neutralization of the hydrochloride—exhibits rapid hydrolytic degradation of the chloromethyl moiety to the corresponding hydroxymethyl analogue. This sensitivity imposes a strict process envelope: in-situ generation and immediate quenching of the free amine are mandatory for any nucleophilic substitution. On a production scale, batch records from multi‑purpose GMP reactors (glass‑lined, 500–2000 L) demonstrate that the alkylation of a secondary amine with 1.05–1.15 eq of 5-(chloromethyl)thiazole hydrochloride in the presence of 1.2–1.5 eq of potassium carbonate in anhydrous DMF at 0–5 °C reaches > 95% conversion within 4 hours. The product, an N‑alkylated thiazole intermediate central to the synthesis of the HIV‑1 protease inhibitor ritonavir, is isolated by drowning into ice‑water and extracting into ethyl acetate. Residual palladium—when a prior Sonogashira coupling is part of the forward route—is scrubbed to <10 ppm using a trimercaptotriazine functionalized silica gel, complying with Ph.Eur. 2.4.8 and USP <232>/<233> elemental impurity limits. The isolated intermediate is then telescoped into a deprotection and coupling sequence without drying to avoid thermal instability; devitrification of the amorphous dispersion has been observed when residual DMF exceeds 100 ppm, a control point verified by headspace GC.

What Drives the Stringent Electrophile Handling Protocol in Cefditoren Pivoxil Side‑Chain Assembly?

The manufacturing route to cefditoren pivoxil—a third‑generation cephalosporin prodrug ester—requires the introduction of a (Z)‑2‑(5‑amino‑1,3,4‑thiadiazol‑2‑yl)‑2‑methoxyiminoacetyl group at the 7‑position of the 7‑aminocephalosporanic acid core. In several patented industrial syntheses, the C‑3 vinyl side‑chain is constructed via a Wittig or Horner‑Wadsworth‑Emmons reaction utilizing a phosphonium salt or phosphonate that bears a thiazole heterocycle. 5‑(Chloromethyl)thiazole hydrochloride serves as the electrophilic component to generate the corresponding thiazolylmethyltriphenylphosphonium chloride under phase‑transfer conditions. The critical process parameter is the absence of adventitious water, which would promote hydrolysis of the chloromethyl group prior to phosphonium formation. Full‑scale production is executed in acetonitrile with 1.0 eq of triphenylphosphine and a catalytic amount of sodium iodide (0.05 eq) at reflux (81–82 °C) for 6–8 hours; the hydrochloride salt is neutralized in situ by the phosphine, obviating the need for an additional base. After precipitation with methyl tert‑butyl ether, the phosphonium salt is isolated with a purity exceeding 99.0% by ³¹P NMR. The subsequent Wittig olefination with the cephalosporin aldehyde proceeds with a Z/E selectivity of >95:5 at −15 °C using lithium hexamethyldisilazide as the base. This sequence is fully documented in drug master files submitted to the PMDA and EMA, and the final active pharmaceutical ingredient must meet JP XVIII and Ph.Eur. 10.0 monographs, including a limit of ≤0.10% for the E‑isomer and total impurities ≤0.5% as per related substances tests. A pilot‑plant investigation revealed that oxygen ingress during the phosphonium salt drying step accelerates oxidation to triphenylphosphine oxide, a contaminant that poisons the ylide formation; blanketting with nitrogen and a vacuum drying endpoint of ≤1.0% residual solvent prevents batch rejection.

Process Robustness for Thiazole Ring Alkylation in Lopinavir Intermediate Preparation

Lopinavir, co‑formulated with ritonavir as a fixed‑dose combination, contains a (2S,3S,5S)‑2‑amino‑3‑hydroxy‑5‑(tert‑butyl)‑1,6‑diphenylhexane scaffold decorated with a thiazolylmethoxycarbonyl moiety. The convergent synthesis attaches the thiazole group by reacting 5‑(chloromethyl)thiazole hydrochloride with a partially protected amino alcohol in a biphasic toluene‑water system using sodium bicarbonate as the acid acceptor. The hydrochloride is partitioned between the phases; free‑basing into the organic layer prevents the accumulation of corrosive chloride ions, which have been linked to pitting corrosion in stainless‑steel reactors when DMF is the solvent. Optimal stoichiometry has been mapped by design‑of‑experiments: 1.03 eq of the chloromethylthiazole hydrochloride and 1.25 eq of NaHCO₃ at 20–25 °C for 12 hours yields 92% conversion with <2% of the dimeric bis‑alkylated impurity. The product crystallizes directly from the concentrated organic phase upon addition of n‑heptane; the crystalline intermediate shows a melting endotherm at 112–114 °C by DSC and complies with residual solvent limits for toluene (≤890 ppm) and n‑heptane (≤5000 ppm) aligned with ICH Q3C Option 1. On a 1500 L scale, a transient emulsion known to entrain aqueous bicarbonate droplets has been mitigated by adjusting the agitation profile to 120–150 rpm with a retreat‑curve impeller, reducing the downstream washing burden by half. The finished intermediate is subjected to full ICH Q3A impurity profiling; any single unspecified impurity exceeding 0.10% triggers a mandatory re‑crystallization from isopropanol/water.

When Albaconazole Requires a Chloromethyl Thiazole Building Block for Antifungal Activity Optimization

Albaconazole is a triazole antifungal agent that derives its broad‑spectrum potency from a quinazolinone‑thiazole hybrid pharmacophore. The pendant thiazole ring is introduced at a late stage via O‑alkylation of a phenolic intermediate with 5‑(chloromethyl)thiazole. The hydrochloride salt must be converted to the free base immediately before use by treatment with aqueous potassium hydroxide in dichloromethane; the organic layer is dried over molecular sieves 4Å to a water specification of <100 ppm. Under anhydrous conditions, the coupling is performed with 1.5 eq of cesium carbonate in DMSO at 40 °C for 8 hours. Extended reaction time or higher temperature (> 50 °C) generates up to 11% of an N‑alkylated regioisomer arising from competing attack at the quinazolinone lactam nitrogen, a side reaction confirmed by ¹H‑¹⁵N HMBC. The desired O‑alkylated product is isolated by silica gel chromatography with a typical recovery of 78–82% and a chromatographic purity > 99.5%. Environmental monitoring during kilo‑lab campaigns determined that the hydrolyzed hydroxymethyl impurity, which is devoid of antifungal activity, forms at a rate of 0.2% per hour when the neutralized base is left in solution at ambient relative humidity > 60%; thus, a “neutralize‑and‑use” work‑in‑process hold time of ≤30 minutes is enforced. The final albaconazole API complies with a residual DMSO limit of ≤5000 ppm and a cesium limit of ≤100 ppm as per USP <233>, justifying the extra washing steps despite yield loss.

Agricultural Fungicide Intermediates and the Role of Heterocyclic Chlorides in Succinate Dehydrogenase Inhibitor Discovery

Modern carboxamide fungicides belonging to the succinate dehydrogenase inhibitor (SDHI) class frequently incorporate a thiazole ring to modulate lipophilicity and target-site binding. In the early‑phase synthesis of N‑(2‑substituted‑5‑thiazolyl)‑1‑methyl‑3‑trifluoromethyl‑1H‑pyrazole‑4‑carboxamide analogues, 5‑(chloromethyl)thiazole hydrochloride serves as a convenient handle for introducing the thiazole nucleus via a two‑step sequence: base‑promoted S‑alkylation with a thiourea derivative followed by cyclodehydration with chloroacetyl chloride. The reaction is run in a mixture of acetone and water (4:1 v/v) with potassium carbonate (2.2 eq) at 0–5 °C for the S‑alkylation, then heated to 60 °C for the cyclocondensation; both steps are telescoped into a single vessel to avoid isolation of the hygroscopic intermediate. Pilot‑scale runs in 200 L glass‑lined reactors have experienced occasional baffle‑zone agglomeration when the intermediate thiazole hydrochloride precipitates prematurely, a process upset corrected by inverse addition (adding the chloromethylthiazole solution to the thiourea mixture) and maintaining a minimum stirrer Reynolds number of 3000. The target pyrazole‑thiazole carboxamide is purified by recrystallization from ethanol/water, affording a technical‑grade material with >97% purity suitable for glasshouse screening. While not yet registered as a commercial active ingredient, the milligram‑to‑kilogram scale‑up data are captured in OECD GAP‑aligned pesticide chemistry dossiers; the amino acid sequence alignment of fungal SDH mutants further validates the retained binding affinity for the thiazole‑substituted pharmacophore.The construction of unsymmetrical cyanine dyes for nucleic acid detection often relies on a quaternized nitrogen heterocycle as the electron‑withdrawing acceptor. 5‑(Chloromethyl)thiazole hydrochloride, after anion exchange to hexafluorophosphate or tosylate, can be quaternized with 2‑methylbenzothiazole or 1‑methylquinolinium salts to generate asymmetric monomethine dyes that intercalate into double‑stranded DNA with a significant fluorescence enhancement. The key activation step uses trimethylsilyl chloride and sodium iodide in acetonitrile at 50 °C for 3 hours to generate the reactive iodomethyl derivative in situ; the quaternization with the base heterocycle proceeds immediately at room temperature. The crude dye is precipitated from diethyl ether and purified by reverse‑phase flash chromatography, with a typical molar absorptivity >70,000 M⁻¹cm⁻¹ at the absorption maximum. Batch records indicate that the presence of residual lithium chloride from a prior ion metathesis step quenches quantum yield below 0.1; a conductivity threshold of <50 µS/cm in the aqueous wash phase guarantees removal. These dyes are released for research‑use‑only applications and are not subject to pharmacopoeial monographs, but the manufacturing facility maintains ISO 13485:2016 certification for oligonucleotide‑conjugated diagnostic reagents, imposing control over cyanine dye lot‑to‑lot spectral consistency assessed via absorbance ratio A₂₆₀/A_max.

Typical impurity profile of 5-(chloromethyl)thiazole HCl for ritonavir intermediate campaigns (lot release panel)

Impurity	Origin	Acceptance Criterion	Analytical Method
5‑(Hydroxymethyl)thiazole	Hydrolysis of chloromethyl group	≤0.50% area	GC‑FID (DB‑WAX, 30 m x 0.32 mm, 0.25 µm)
5‑(Bromomethyl)thiazole	Halogen exchange with residual NaBr	≤0.15% area	HPLC‑UV 254 nm (C18, MeCN/phosphate pH 3.0)
2‑(Chloromethyl)thiazole isomer	Regioisomeric impurity from ring synthesis	≤0.10% area	1H NMR (600 MHz, DMSO‑d6)
Thiazole	De‑chloromethylation degradation	≤0.05% area	HS‑GC‑MS (SIM, m/z 85)
Total unidentified impurities	—	≤0.20% area	HPLC‑UV 254 nm
Residual palladium	Carryover from upstream coupling	≤10 ppm	ICP‑MS (USP <233>)
Water content	Moisture uptake	≤0.50% w/w	Karl Fischer coulometry (USP <921>, Method Ic)

A Non‑GMP Starting Material’s Divergent Stability Under Extended Supply‑Chain Logistics

The shelf‑life assignment of 5‑(chloromethyl)thiazole hydrochloride diverges from that of downstream advanced intermediates because it is still classified as a non‑isolated starting material in some regulatory filings yet is shipped under ambient conditions in fiber drums with an LDPE liner. Accelerated stability data generated according to ICH Q1A ( 40 °C/75% RH for 6 months ) show that the hydrochloride remains within specification except for a gradual discoloration from white to pale yellow detectable as an absorbance increase at 420 nm of a 10% w/v methanolic solution. The discoloration does not correlate with a decrease in assay but has been traced to a ring‑opening pathway generating volatile sulfur compounds that catalyze further degradation; addition of 0.1% w/w of ethylenediaminetetraacetic acid disodium salt dihydrate as a chelator suppresses this autocatalytic loop. For intercontinental cargo that may experience temperatures above 40 °C inside a container, the supplier’s shipment validation mandates a validated reefer set‑point of +5 °C and inclusion of a temperature logger meeting WHO PQS E006 requirements. Importers holding a GDUFA‑compliant Type II drug master file routinely communicate any observed deliquescence upon prolonged exposure to > 85% RH and recommend immediate use upon opening a new drum. The absence of an FDA‑recognized compendial monograph for the substance means that reprocessing of out‑of‑specification material requires a formal change control review against the customer’s internal release specification, frequently referencing Ph.Eur. 5.17.2 on the handling of APIs and excipients.